Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis announces three-year deal

Sanofi-Aventis announces three-year deal

27th November 2008

Sanofi-Aventis has announced a three-year contract to extend the use of Advanced Chemistry Development (ACD/Labs) software in its research and development sites.

The deal will see a special pricing structure and provisions for continuing support.

Sanofi-Aventis already uses a range of ACD/Labs’ analytical, nomenclature and predictive tools, including ACD/Structure Design Suite, ACD/Name and ACD/SpecManager, among others.

Director of sales for Chemcad – a distributor of ACD/Labs products – said the contract will allow for a continuation of the same high level of support, adding it will also allow for research and development scientists to maximise the “intrinsic value” of each of the modules used.

He added: “Sanofi-Aventis has been using ACD/Labs tools in its R&D groups throughout the organisation for more than five years.”

Earlier this month, the company has announced they are to discontinue all clinical trials with rimonabant.

The cancelling of the rimonabant clinical development program will be in all indications and has been taken in light of recent demands by certain national health authorities.

Sanofi-Aventis has seven major therapy areas, which are cardiovascular medicine, thrombosis, oncology, internal medicine, metabolic disorders, diseases of the central nervous system and vaccines.

Its products include Plavix (clopidogrel bisulfate), Clexane (enoxaparin sodium), Telfast (fexofenadine), Lantus (insulin glargine) and Taxotere (docetaxel), among others.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.